ABT

$110.283.84%4.08

시간 외 거래: 110.44+0.16 +0.15%

Abbott Laboratories (ABT)

Date: O: H: L: C: Vol:

전일 마감가:

$106.20

열려 있는:

$106.89

하루 거래량:

7,355,994

상대 거래량:

0.72

시가총액:

$190.83B

수익:

$46.59B

순이익/손실:

$5.41B

주가수익비율:

35.65

EPS:

$3.09

순현금흐름:

$7.38B

1W 성능:

+5.15%

1M 성능:

+13.11%

6M 성능:

+23.27%

1Y 성능:

-10.79%

1일 변동 폭

$106.40$110.48

1주일 범위

$101.54$110.48

52주 변동 폭

$81.97$132.03

Abbott Laboratories 주식 (ABT) 회사 개요

명칭

Abbott Laboratories

부문

Healthcare

산업

Medical Devices

전화

(224) 667-6100

주소

100 ABBOTT PARK ROAD, ABBOTT PARK, IL, USA

직원

115,000

@AbbottNews

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 ABT에 대한 토론

ABT vs MDT, SYK, BSX, EW 비교

주식	시가총액	매출	순이익	현금흐름	주당 순 이익
ABT Abbott Laboratories	$190.83B	$45.13B	$6.28B	$7.38B	$3.09
MDT Medtronic Plc	$127.03B	$37.54B	$5.23B	$6.13B	$3.73
SYK Stryker Corp	$117.68B	$26.30B	$3.62B	$4.57B	$8.63
BSX Boston Scientific Corp	$64.24B	$21.07B	$3.50B	$3.33B	$2.38
EW Edwards Lifesciences Corp	$53.76B	$6.51B	$1.00B	$1.43B	$1.84

Abbott Laboratories 주식(ABT) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-10-27	다운그레이드	Argus	Buy → Hold
2026-10-07	개시	Barclays	Overweight
2026-10-02	업그레이드	Rothschild & Co Redburn	Neutral → Buy
2026-08-13	업그레이드	Wolfe Research	Peer Perform → Outperform
2026-07-01	개시	Robert W. Baird	Outperform
2026-04-22	다운그레이드	Daiwa Securities	Outperform → Neutral
2025-10-10	개시	The Benchmark Company	Buy
2025-07-18	업그레이드	Jefferies	Hold → Buy
2025-06-16	개시	Leerink Partners	Market Perform
2024-10-08	개시	Oppenheimer	Outperform
2024-09-19	개시	Piper Sandler	Overweight
2024-07-30	다운그레이드	Edward Jones	Buy → Hold
2024-05-30	개시	Goldman	Buy
2023-07-21	업그레이드	Wolfe Research	Underperform → Peer Perform
2023-05-30	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2023-04-20	재확인	Barclays	Overweight
2023-04-20	재확인	Bernstein	Outperform
2023-04-20	재확인	JP Morgan	Overweight
2023-04-20	재확인	Raymond James	Outperform
2023-04-20	재확인	UBS	Buy
2023-04-20	재확인	Wolfe Research	Underperform
2023-03-29	개시	UBS	Buy
2022-10-26	개시	Mizuho	Neutral
2022-10-18	개시	Barclays	Overweight
2022-10-12	개시	Jefferies	Hold
2022-07-06	개시	Wolfe Research	Underperform
2022-03-02	Resumed	BofA Securities	Buy
2022-01-27	재확인	Credit Suisse	Outperform
2022-01-27	재확인	Morgan Stanley	Overweight
2022-01-27	재확인	Raymond James	Outperform
2022-01-27	재확인	UBS	Buy
2021-12-10	개시	RBC Capital Mkts	Outperform
2021-10-27	업그레이드	Atlantic Equities	Neutral → Overweight
2021-10-14	개시	Redburn	Neutral
2021-05-25	개시	Barclays	Overweight
2021-04-15	개시	Atlantic Equities	Neutral
2021-01-28	업그레이드	BTIG Research	Neutral → Buy
2020-09-11	개시	Wolfe Research	Outperform
2020-06-01	다운그레이드	Goldman	Neutral → Sell
2020-03-05	개시	Citigroup	Buy
2020-02-13	개시	Goldman	Neutral
2020-02-06	Resumed	BTIG Research	Neutral
2020-01-02	다운그레이드	Guggenheim	Buy → Neutral
2019-06-13	재확인	BofA/Merrill	Buy
2019-02-07	재확인	BofA/Merrill	Buy
2019-01-02	다운그레이드	Citigroup	Neutral → Sell
2018-11-30	업그레이드	Goldman	Neutral → Buy
2018-10-16	개시	Barclays	Overweight
2018-06-27	개시	Bernstein	Outperform
2018-01-30	재확인	Citigroup	Neutral
2018-01-25	재확인	Stifel	Buy
2018-01-25	업그레이드	William Blair	Mkt Perform → Outperform
2018-01-03	개시	Evercore ISI	Outperform
2018-01-02	업그레이드	JP Morgan	Neutral → Overweight
2018-01-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2017-10-19	재확인	RBC Capital Mkts	Outperform
2017-10-19	재확인	Stifel	Buy

Abbott Laboratories (ABT) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	44,328.00	41,950.00	40,109.00	43,653.00	43,075.00
Cost of revenue USD (M)	19,319.00	18,706.00	17,975.00	19,142.00	18,537.00
Gross profit USD (M)	-	-	22,134.00	24,511.00	24,538.00
Research and development USD (M)	2,942.00	2,844.00	2,741.00	2,888.00	2,742.00
Operating expenses USD (M)	36,275.00	35,125.00	15,656.00	16,149.00	16,113.00
Operating income USD (M)	8,053.00	6,825.00	6,478.00	8,362.00	8,425.00
Income before tax USD (M)	8,466.00	7,013.00	6,664.00	8,306.00	8,211.00
Income tax expense USD (M)	1,942.00	-6,389.00	941.00	1,373.00	1,140.00
Net income USD (M)	6,524.00	13,402.00	5,723.00	6,933.00	7,071.00
Basic EPS USD/shares	3.73	7.67	3.28	3.94	3.97
Diluted EPS USD/shares	3.72	7.64	3.26	3.91	3.94
Basic weighted shares shares (M)	1,741.00	1,740.00	1,740.00	1,753.00	1,775.00
Diluted weighted shares shares (M)	1,748.00	1,748.00	1,749.00	1,764.00	1,789.00
Selling, general and administrative USD (M)	12,332.00	11,697.00	10,949.00	11,248.00	11,324.00

Abbott Laboratories 주식 (ABT) 내부자 거래

John A. McCoy, Jr.Sep 02 '26
Officer
거래
Proposed Sale
비용
$109.52
#주식
27
가치 ($)
2,957
#주식 총계
0
MCCOY JOHN A. JR.Sep 02 '26
VICE PRESIDENT AND CONTROLLER
거래
Sale
비용
$109.54
#주식
27
가치 ($)
2,958
#주식 총계
24,549
Ford Robert BAug 25 '26
CHAIRMAN AND CEO
거래
Sale
비용
$115.85
#주식
398,832
가치 ($)
46,204,798
#주식 총계
306,461
Ford Robert BAug 25 '26
CHAIRMAN AND CEO
거래
Option Exercise
비용
$54.02
#주식
398,832
가치 ($)
21,545,946
#주식 총계
705,293
Robert B. FordAug 25 '26
Officer
거래
Proposed Sale
비용
$115.85
#주식
398,832
가치 ($)
46,204,386
#주식 총계
0
Morrone Louis H.Aug 11 '26
EXECUTIVE VICE PRESIDENT
거래
Sale
비용
$109.83
#주식
5,850
가치 ($)
642,506
#주식 총계
70,724
Louis H. MorroneAug 11 '26
Officer
거래
Proposed Sale
비용
$109.83
#주식
5,850
가치 ($)
642,506
#주식 총계
0
Robert J. AlpernMay 15 '26
Retired Director
거래
Proposed Sale
비용
$85.25
#주식
7,587
가치 ($)
646,791
#주식 총계
0
Stratton John GMay 07 '26
Director
거래
Buy
비용
$86.82
#주식
2,000
가치 ($)
173,640
#주식 총계
23,319
STARKS DANIEL JApr 27 '26
Director
거래
Buy
비용
$92.65
#주식
10,000
가치 ($)
926,537
#주식 총계
6,751,103

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
John A. McCoy, Jr.	Officer	Sep 02 '26	Proposed Sale	$109.52	27	2,957	0
MCCOY JOHN A. JR.	VICE PRESIDENT AND CONTROLLER	Sep 02 '26	Sale	$109.54	27	2,958	24,549
Ford Robert B	CHAIRMAN AND CEO	Aug 25 '26	Sale	$115.85	398,832	46,204,798	306,461
Ford Robert B	CHAIRMAN AND CEO	Aug 25 '26	Option Exercise	$54.02	398,832	21,545,946	705,293
Robert B. Ford	Officer	Aug 25 '26	Proposed Sale	$115.85	398,832	46,204,386	0
Morrone Louis H.	EXECUTIVE VICE PRESIDENT	Aug 11 '26	Sale	$109.83	5,850	642,506	70,724
Louis H. Morrone	Officer	Aug 11 '26	Proposed Sale	$109.83	5,850	642,506	0
Robert J. Alpern	Retired Director	May 15 '26	Proposed Sale	$85.25	7,587	646,791	0
Stratton John G	Director	May 07 '26	Buy	$86.82	2,000	173,640	23,319
STARKS DANIEL J	Director	Apr 27 '26	Buy	$92.65	10,000	926,537	6,751,103

Abbott Laboratories 주식(ABT)의 최신 뉴스

Nov 02, 2026

Thomas H. Kean Jr reports Abbott Laboratories sale, ESAB purchase By Investing.com - Investing.com Nigeria

Nov 02, 2026

Thomas H. Kean Jr reports Abbott Laboratories sale, ESAB purchase - Investing.com

Nov 02, 2026

FDA baby formula rules revamp adds potential complication to Abbott spinoff - Crain's Chicago Business

Nov 02, 2026

Abbott Laboratories (ABT) Posts Positive SonicForce Trial Data, Is The Stock A Bargain? - Simply Wall St

Nov 02, 2026

Nov 01, 2026

Abbott's TECTONIC clinical trial demonstrates strong 30-day... - Quantisnow

Nov 01, 2026

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy? - The Motley Fool

Nov 01, 2026

Oct 30, 2026

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

Oct 30, 2026

Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears? - Yahoo Finance

Oct 30, 2026

JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

Abbott To Spin Off $8.5B Nutrition Business Into Standalone Public Company - https://en.edairynews.com/

Oct 28, 2026

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact - The Motley Fool

Oct 28, 2026

Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com

Oct 27, 2026

Abbott: Demand Headwinds & Litigation Risks Priced-In - Spin-Off Tailwinds Ahead (ABT) - Seeking Alpha

Oct 27, 2026

Argus Downgrades Abbott Laboratories to Hold From Buy - marketscreener.com

Oct 27, 2026

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Zacks Investment Research

Oct 27, 2026

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Yahoo Finance

Oct 27, 2026

In Ga. District Court, Product Liability Claim Over Abbott Laboratories' Heart Valve Filed - Law.com

Oct 26, 2026

Abbott Laboratories: A New Growth Story Takes Shape (NYSE:ABT) - Seeking Alpha

Oct 26, 2026

Oct 24, 2026

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool

Oct 24, 2026

Oct 23, 2026

No change to CG operations as Abbott announces plans to separate nutrition business - PinalCentral.com

Oct 23, 2026

What the $8.5B Abbott Nutrition spinoff means for Columbus - The Business Journals

Oct 23, 2026

Oct 22, 2026

Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device - GlobeNewswire Inc.

Oct 22, 2026

Oct 21, 2026

Abbott Laboratories announces a baby formula spinoff company - Marketplace.org

Oct 21, 2026

Abbott: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Oct 21, 2026

Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas - Chicago Tribune

Oct 21, 2026

Abbott to Carve Out Nutrition Business Into Independent Company - WSJ

Oct 21, 2026

Pre-Markets in Green on Strong Earnings Results - Zacks Investment Research

Oct 21, 2026

Pre-Markets Up on Cooling Metrics, Decent Q3 Reports - Zacks Investment Research

Oct 21, 2026

Abbott Laboratories to spin off nutrition unit at centre of baby formula lawsuits - Financial Times

Oct 21, 2026

Abbott (ABT) Misses Q3 Earnings Estimates - Zacks Investment Research

Oct 21, 2026

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

Oct 21, 2026

Abbott cuts 2026 sales growth view, plans to spin off nutrition business - Reuters

Oct 21, 2026

Abbott Spins Off Embattled Business That Sells Baby Formula - Bloomberg

Oct 21, 2026

Abbott plans to spin out its nutrition business - MedTech Dive

Oct 21, 2026

Abbott: 3 Key Takeaways for Long-Term Investors - Yahoo Finance

Oct 21, 2026

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company - Yahoo Finance

Oct 21, 2026

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027 - Yahoo Finance

Oct 21, 2026

Abbott Stock Falls After Earnings. It’s Shedding Its Troubled Nutrition Unit. - Barron's

Oct 21, 2026

Oct 20, 2026

Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test - Yahoo Finance

Oct 20, 2026

Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock - Trefis

Oct 20, 2026

Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? - Yahoo Finance

Oct 20, 2026

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool

Oct 20, 2026

Abbott Q3 preview: What to expect (ABT:NYSE) - Seeking Alpha

Oct 20, 2026

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services - The Globe and Mail

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

Oct 20, 2026

How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings - Benzinga

Oct 20, 2026

ABT와(과) 유사한 종목

Abbott Laboratories (ABT)

Abbott Laboratories 주식 (ABT) 회사 개요

ABT vs MDT, SYK, BSX, EW 비교

Abbott Laboratories 주식(ABT) 업그레이드 및 다운그레이드

Abbott Laboratories (ABT) 재무 분석

Abbott Laboratories 주식 (ABT) 내부자 거래

Abbott Laboratories 주식(ABT)의 최신 뉴스

Thomas H. Kean Jr reports Abbott Laboratories sale, ESAB purchase By Investing.com - Investing.com Nigeria

Thomas H. Kean Jr reports Abbott Laboratories sale, ESAB purchase - Investing.com

FDA baby formula rules revamp adds potential complication to Abbott spinoff - Crain's Chicago Business

Abbott Laboratories (ABT) Posts Positive SonicForce Trial Data, Is The Stock A Bargain? - Simply Wall St

Abbott's TECTONIC clinical trial demonstrates strong 30-day... - Quantisnow

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy? - The Motley Fool

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears? - Yahoo Finance

JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? - Zacks Investment Research

Abbott To Spin Off $8.5B Nutrition Business Into Standalone Public Company - https://en.edairynews.com/

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact - The Motley Fool

Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday - Yahoo Finance

Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com

Abbott: Demand Headwinds & Litigation Risks Priced-In - Spin-Off Tailwinds Ahead (ABT) - Seeking Alpha

Argus Downgrades Abbott Laboratories to Hold From Buy - marketscreener.com

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Zacks Investment Research

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Yahoo Finance

Abbott plans to spin off its nutrition business by end of 2027 - Quartz

This Dividend King Just Announced Great News for Investors - The Motley Fool

This Dividend King Just Announced Great News for Investors - The Motley Fool

In Ga. District Court, Product Liability Claim Over Abbott Laboratories' Heart Valve Filed - Law.com

Abbott Laboratories: A New Growth Story Takes Shape (NYSE:ABT) - Seeking Alpha

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool

No change to CG operations as Abbott announces plans to separate nutrition business - PinalCentral.com

What the $8.5B Abbott Nutrition spinoff means for Columbus - The Business Journals

Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device - GlobeNewswire Inc.

Abbott Laboratories announces a baby formula spinoff company - Marketplace.org

Abbott: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas - Chicago Tribune

Abbott to Carve Out Nutrition Business Into Independent Company - WSJ

Pre-Markets in Green on Strong Earnings Results - Zacks Investment Research

Pre-Markets Up on Cooling Metrics, Decent Q3 Reports - Zacks Investment Research

Abbott Laboratories to spin off nutrition unit at centre of baby formula lawsuits - Financial Times

Abbott (ABT) Misses Q3 Earnings Estimates - Zacks Investment Research

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

Abbott cuts 2026 sales growth view, plans to spin off nutrition business - Reuters

Abbott Spins Off Embattled Business That Sells Baby Formula - Bloomberg

Abbott plans to spin out its nutrition business - MedTech Dive

Abbott: 3 Key Takeaways for Long-Term Investors - Yahoo Finance

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company - Yahoo Finance

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027 - Yahoo Finance

Abbott Stock Falls After Earnings. It’s Shedding Its Troubled Nutrition Unit. - Barron's

Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test - Yahoo Finance

Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock - Trefis

Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? - Yahoo Finance

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool

Abbott Q3 preview: What to expect (ABT:NYSE) - Seeking Alpha

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services - The Globe and Mail

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings - Benzinga

ABT와(과) 유사한 종목